Abstract
The tachykinins, substance P, neurokinin A and neurokinin B are small peptides expressed in the extrinsic primary afferent nerve fibers and enteric neurons of the gut. Tachykinins exert a variety of biological actions mediated by three distinct receptors, termed NK1, NK2 and NK3, and at the gastrointestinal level these peptides influence motility, electrolyte and fluid secretion and tissue homeostasis. Several intestinal disorders are associated with changes in the expression of the tachykinin system. Thanks to biological studies and receptor cloning, new selective tachykinins antagonists are now available and have been shown to be active in experimental gut disorders. Some of them are now under clinical trial in inflammatory bowel diseases and the irritable bowel syndrome. The body of preclinical data so far available seems to indicate that tachykinin antagonists might be a new therapeutic tool in the treatment of gut disorders.
Current Pharmaceutical Design
Title: Involvement of Tachykinins in Intestinal Inflammation
Volume: 7 Issue: 1
Author(s): S. Evangelista
Affiliation:
Abstract: The tachykinins, substance P, neurokinin A and neurokinin B are small peptides expressed in the extrinsic primary afferent nerve fibers and enteric neurons of the gut. Tachykinins exert a variety of biological actions mediated by three distinct receptors, termed NK1, NK2 and NK3, and at the gastrointestinal level these peptides influence motility, electrolyte and fluid secretion and tissue homeostasis. Several intestinal disorders are associated with changes in the expression of the tachykinin system. Thanks to biological studies and receptor cloning, new selective tachykinins antagonists are now available and have been shown to be active in experimental gut disorders. Some of them are now under clinical trial in inflammatory bowel diseases and the irritable bowel syndrome. The body of preclinical data so far available seems to indicate that tachykinin antagonists might be a new therapeutic tool in the treatment of gut disorders.
Export Options
About this article
Cite this article as:
S. Evangelista , Involvement of Tachykinins in Intestinal Inflammation, Current Pharmaceutical Design 2001; 7 (1) . https://dx.doi.org/10.2174/1381612013398446
DOI https://dx.doi.org/10.2174/1381612013398446 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prospects for Developing New Antibacterials Targeting Bacterial Type IIA Topoisomerases
Current Topics in Medicinal Chemistry Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development
Current Medicinal Chemistry Cysteinet Dysregulation in Muscular Dystrophies: A Pathogenic Network Susceptible to Therapy
Current Medicinal Chemistry Fullerenes: From Carbon to Nanomedicine
Mini-Reviews in Medicinal Chemistry Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease
Current Pharmaceutical Design Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design New Immunosuppressants in Clinical Trial
Current Drug Targets - Cardiovascular & Hematological Disorders HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective
Current HIV Research Chlorophytum borivilianum: A White Gold for Biopharmaceuticals and Neutraceuticals
Current Pharmaceutical Biotechnology Effects of Evolocumab on Cardiovascular Events
Current Cardiology Reviews Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Transbronchial Needle Aspiration (TBNA): Past Present and Future
Current Respiratory Medicine Reviews Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews